- Thinly traded micro cap Oasmia Pharmaceutical AB (OTC:OASM) is up 28% premarket on average volume on the heels of a positive opinion from the European Medicines Agency's advisory group CHMP backing approval for Apealea (paclitaxel micellar), combined with carboplatin, for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
- A final decision from the European Commission usually takes ~60 days.
European advisory group backs Oasmia's Apealea in ovarian cancer; shares up 28% premarket
Recommended For You
More Trending News
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
OASM | - | - |
Oasmia Pharmaceutical AB (publ) |